Prevention of Cardiac Dysfunction During Breast Cancer Therapy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 138 participants.

Also called NCT03760588

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 138 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03760588
Other papers using this trial's data
  • Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial Circulation, 2025-10-21 DOI, PubMed 40884047, PMC12537036 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Norway (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03760588. Randomized; quadruple masking; primary purpose prevention. Start 2019-01-31 (actual); primary completion 2024-09-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prevention of Cardiac Dysfunction During Breast Cancer Therapy
Acronym
PRADAII
Condition
Breast Cancer Female
Condition
Heart Failure
Intervention (Drug)
Sacubitril/valsartan
Lead sponsor
Torbjorn Omland (class: other)
Collaborator
University Hospital, Akershus (class: other)
Collaborator
Oslo University Hospital (class: other)
Collaborator
University Hospital of North Norway (class: other)
Collaborator
St. Olavs Hospital (class: other)
Collaborator
Helse Stavanger HF (class: other government)
Collaborator
Klinbeforsk (class: other)
Collaborator
Norwegian Cancer Society (class: other)
Collaborator
Novartis (class: industry)

Record details

Record id
cardio:ct-nct03760588
Content hash
a1c1e8aca223fe86ce8108f4b0b90a8bbaa52cc51ec5c68b24affb4bcec48511